LTR PHARMA LIMITED ORDINARY (LTP) Short Interest
LTR PHARMA LIMITED ORDINARY (ASX:LTP) had 0.09% of shares reported as short positions as of 16 July 2026, representing 166,274 shares. LTR PHARMA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Ltr Pharma
LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4LTP intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Ltr Pharma
Latest LTP news
All news- Notification regarding unquoted securities - LTP
asx
- Is LTR Pharma (ASX: LTP) Losing Momentum After a Strong One-Year Gain? - Kalkine
googlenews
- LTR Pharma (ASX:LTP) in Focus as Speculative Interest Shifts - Kalkine
googlenews
- OROFLOW Clinical Study Receives Ethics Approval
asx
- Linius Technologies (ASX: LTP) Sparks Fresh Tech Buzz as AI Video and Digital Media Themes Build - Kalkine
googlenews
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss LTP
Start a research thread or post the first pulse update